Prosecution Insights
Last updated: August 06, 2026

Mexichem Fluor S A De C V

16 pending office actions • 7 art units • 9 examiners • 0 of 16 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

16
Total Pending OAs
12
Non-Final OAs
2
Final Rejections
2
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

8
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (8)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

5
Hard (31%)
3
Medium (19%)
6
Easy (38%)
2
Unknown (12%)

Rejection Statute Mix

BucketCases
§103 only3 (19%)
Double-patenting only6 (38%)
Multi-statute (no §101)5 (31%)
No statute on record2 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

16
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

160 h
Manual time on pending OAs
32 h
Time saved (low, 20%)
56 h
Time saved (mid, 35%)
1.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SAEED, ALI S 4 31.2% +34.3%
BASQUILL, SEAN M 3 38.8% +21.7%
HAGHIGHATIAN, MINA 3 45.7% +39.8%
CUTLIFF, YATE KAI RENE 1 79.9% +24.1%
DIAZ, MATTHEW R 1 53.4% +44.0%
BAHTA, MEDHANIT W 1 80.5% +28.7%
DOMONE, CHRISTOPHER P 1 84.0% +20.8%
PATEL, RONAK C 1 51.1% +56.1%
GODENSCHWAGER, PETER F 1 67.9% +17.8%

Hard Cases (5)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18259324 PROCESS FOR THE PRODUCTION OF 1,1-DIFLUOROETHANE BAHTA, MEDHANIT W 25d overdue
17969250 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 15d overdue
18256253 COMPOSITION DOMONE, CHRISTOPHER P 26d
18537034 METHOD FOR PREPARING PARTIALLY FLUORINATED ALCOHOL CUTLIFF, YATE KAI RENE
17795417 COMPOSITIONS GODENSCHWAGER, PETER F

Interview Candidates (16)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
16334156 PHARMACEUTICAL COMPOSITION SAEED, ALI S 35d overdue
17460585 PHARMACEUTICAL COMPOSITION COMPRISING TIOTROPIUM BROMIDE MONOHYDRATE SAEED, ALI S 30d overdue
16582710 PHARMACEUTICAL COMPOSITION SAEED, ALI S 30d overdue
16582964 PHARMACEUTICAL COMPOSITION SAEED, ALI S 30d overdue
18259324 PROCESS FOR THE PRODUCTION OF 1,1-DIFLUOROETHANE BAHTA, MEDHANIT W 25d overdue
17969250 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 15d overdue
17944666 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 15d overdue
17944637 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 15d overdue

Top Art Units

Art UnitApps
1616 7
1614 3
1692 2
1761 1
1725 1
1788 1
1767 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19533595 PHARMACEUTICAL COMPOSITION BASQUILL, SEAN M 1614 DP Final Rejection Pending Feb 09, 2026
18537034 METHOD FOR PREPARING PARTIALLY FLUORINATED ALCOHOL CUTLIFF, YATE KAI RENE 1692 §102§112 Non-Final OA Pending Dec 12, 2023
18489133 PHARMACEUTICAL COMPOSITION BASQUILL, SEAN M 1614 Other Non-Final OA 36d Pending Oct 18, 2023
18489150 PHARMACEUTICAL COMPOSITION BASQUILL, SEAN M 1614 Other Non-Final OA Pending Oct 18, 2023
18473507 COMPOSITIONS DIAZ, MATTHEW R 1761 §103Other Final Rejection Pending Sep 25, 2023
18259324 PROCESS FOR THE PRODUCTION OF 1,1-DIFLUOROETHANE BAHTA, MEDHANIT W 1692 §102§103§112Other Non-Final OA 25d overdue Pending Jun 26, 2023
18256253 COMPOSITION DOMONE, CHRISTOPHER P 1725 §102§103§112Other Non-Final OA 26d Pending Jun 07, 2023
18141157 FLUORITE SYNTHETIC STONES AND METHOD OF MAKING FLUORITE SYNTHETIC STONES PATEL, RONAK C 1788 §103 Non-Final OA Pending Apr 28, 2023
17969250 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 1616 §103§112Other Non-Final OA 15d overdue Pending Oct 19, 2022
17944666 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 1616 §103Other Non-Final OA 15d overdue Pending Sep 14, 2022
17944637 PHARMACEUTICAL COMPOSITION HAGHIGHATIAN, MINA 1616 DP Non-Final OA 15d overdue Pending Sep 14, 2022
17795417 COMPOSITIONS GODENSCHWAGER, PETER F 1767 §102§103§112 Non-Final OA Pending Jul 26, 2022
17460585 PHARMACEUTICAL COMPOSITION COMPRISING TIOTROPIUM BROMIDE MONOHYDRATE SAEED, ALI S 1616 DP Non-Final OA 30d overdue Pending Aug 30, 2021
16582710 PHARMACEUTICAL COMPOSITION SAEED, ALI S 1616 DP Non-Final OA 30d overdue Pending Sep 25, 2019
16582964 PHARMACEUTICAL COMPOSITION SAEED, ALI S 1616 DP Non-Final OA 30d overdue Pending Sep 25, 2019
16334156 PHARMACEUTICAL COMPOSITION SAEED, ALI S 1616 DP Non-Final OA 35d overdue Pending Mar 18, 2019

Managing Mexichem Fluor S A De C V's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month